EMERGENT BIOSOLUTIONS INC. Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate
EMERGENT BIOSOLUTIONS INC. (EBS) reported Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate of 2.10% for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate · last filed 2024-03-08
- EMERGENT BIOSOLUTIONS INC. defined benefit plan, assumptions used calculating net periodic benefit cost, discount rate for fiscal 2022 was 2.10%, a 600.00% increase from fiscal 2021.
- EMERGENT BIOSOLUTIONS INC. defined benefit plan, assumptions used calculating net periodic benefit cost, discount rate for fiscal 2021 was 0.30%, a 1400.00% increase from fiscal 2020.
- EMERGENT BIOSOLUTIONS INC. defined benefit plan, assumptions used calculating net periodic benefit cost, discount rate for fiscal 2020 was 0.02%, a 90.00% decline from fiscal 2019.
- EMERGENT BIOSOLUTIONS INC. defined benefit plan, assumptions used calculating net periodic benefit cost, discount rate for fiscal 2019 was 0.20%, a 77.78% decline from fiscal 2018.
| Period end | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 12 month |
|---|---|
| 2022-12-31 | 2.10% 10-K · filed 2024-03-08 |
| 2021-12-31 | 0.30% 10-K/A · filed 2023-12-11 |
| 2020-12-31 | 0.02% 10-K · filed 2022-02-25 |
| 2019-12-31 | 0.20% 10-K · filed 2021-02-19 |
| 2018-12-31 | 0.90% 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |